Viral myocarditis

Current Opinion in Rheumatology

Volumn 28, Issue 4, 2016, Pages 383-389

  Rose, Noel R ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

cardiac myosin; coxsackievirus B3; dilated cardiomyopathy; myocarditis

Indexed keywords

AUTOIMMUNE DISEASE; AUTOIMMUNITY; CLINICAL FEATURE; COXSACKIEVIRUS B3; HEART MUSCLE BIOPSY; INFECTION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; VIRUS MYOCARDITIS; ADVERSE EFFECTS; ANIMAL; BIOPSY; CARDIOMYOPATHY, DILATED; COMPLICATION; COXSACKIEVIRUS INFECTIONS; DISEASE MODEL; ENTEROVIRUS B; HUMAN; IMMUNOLOGY; MYOCARDITIS; VIROLOGY; VIRUS DISEASES;

ANTIVIRUS AGENT;

ANIMALS; ANTIVIRAL AGENTS; AUTOIMMUNE DISEASES; BIOPSY; CARDIOMYOPATHY, DILATED; COXSACKIEVIRUS INFECTIONS; DISEASE MODELS, ANIMAL; ENTEROVIRUS B, HUMAN; HUMANS; MYOCARDITIS; VIRUS DISEASES;

EID: 84966711498     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000303     Document Type: Review

References (32)

1. Huber SA. Viral myocarditis and dilated cardiomyopathy: etiology and pathogenesis. Curr Pharm Des 2016; 22: 408-426
2. Lumsden RH, Bloomfield GS. The causes of HIV-associated cardiomyopathy: a tale of two worlds. Biomed Res Int 2016; 2016: Article ID 8196560, 9 pages. Myocarditis with essentially the same clinical presentation can be induced by a wide range of vastly different viruses including HIV. It suggests that the disease is determined mainly by the host rather than the infecting agent
3. Fairweather D, Kaya Z, Shellam GR, et al. From infection to autoimmunity. J Autoimmun 2001; 16: 175-186
4. Caforio ALP, Pankuweit S, Arbustini E, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on myocardial and pericardial diseases. Eur Heart J 2013; 34: 2636-2648
5. Kindermann I, Barth C, Mahfoud F, et al. Update on myocarditis. J Am Coll Cardiol 2012; 59: 779-792
6. Cheng Z, Li-Sha G, Yue-Chun L. Autonomic nervous system in viral myocarditis: pathophysiology and therapy. Curr Pharm Des 2016; 22: 485-498
7. Dominguez F, Kühl U, Pieske B, et al. Update on myocarditis and inflammatory cardiomyopathy: reemergence of endomyocardial biopsy. Rev Esp Cardiol (Engl Ed) 2016; 69: 178-187
8. Tschope C, Kuhl U. Myocarditis and inflammatory cardiomyopathy: current treatment options. Dtsch Med Wchenschr 2016; 141: 95-102
9. Fung G, Luo H, Qiu Y. Myocarditis. Circ Res 2016; 118: 496-514
10. Nowalany-Kozielska E, Koziel M, Domal-Kwiatkowska D, et al. Clinical significance of viral genome persistence in the myocardium of patients with dilated cardiomyopathy. Intervirology 2016; 58: 350-356
11. Ciccone MM, Dentamaro I, Carbonara S, et al. Fulminant peripartum myocarditis associated with sudden cardiac death: a case report. Cardiovasc Pathol 2016; 25: 87-89
12. Kuchynka P, Palecek T, Masek M, et al. Current diagnostic and therapeutic aspects of eosinophilic myocarditis. Biomed Res Int 2016; 2016: Article ID 2829583, 6 pages. Eosinophilic myocarditis is a rare but frequently fatal form of the disease. There is no well established treatment. The first animal model of the disease was described recently, which may help in devising better treatments
13. Maleszewski JJ, Orellana VM, Hodge DO, et al. Long-term risk of recurrence, morbidity and mortality in giant cell myocarditis. Am J Cardiol 2015; 115: 1733-1738
14. Afanasyeva M, Wang Y, Kaya Z, et al. Experimental autoimmune myocarditis in A/J mice is an interleukin-4-dependent disease with a Th2 phenotype. Am J Pathol 2001; 159: 193-203
15. Pankuweit S, Lüers C, Richter A, et al. Influence of different aetiologies on clinical course and outcome in patients with dilated cardiomyopathy. Eur J Clin Invest 2015; 45: 906-917
16. Reinthaler M, Empen K, Herda LR, et al. The effect of a repeated immunoadsorption in patients with dilated cardiomyopathy after recurrence of severe heart failure symptoms. J Clin Apheresis 2014; 30: 217-223
17. Yoshikawa T, Baba A, Akaishi M, et al. Immunoadsorption therapy for dilated cardiomyopathy using tryptophan column: a prospective, multicenter, randomized, within-patient and parallel-group comparative study to evaluate efficacy and safety. J Clin Apheresis 2016; 31: 1-9; n. pag. The authors report successful use of an improved IgG3 immunoadsorbant
18. Caforio AL, Angelini A, Blank M, et al. Passive transfer of affinity-purified antiheart autoantibodies (AHA) from sera of patients with myocarditis induces experimental myocarditis in mice. Int J Cardiol 2015; 179: 166-177
19. Feric NT, Radisic M. Strategies and challenges to myocardial replacement therapy. Stem Cells Transl Med 2016; 5: 410-416
20. Caforio AL, Marcolongo R, Basso C, Iliceto S. Clinical presentation and diagnosis of myocarditis. Heart 2015; 101: 1332-1344
21. Mason JW, O'connell JB, Herskowitz A, et al. A clinical trial of immunosuppressive therapy for myocarditis. N Engl J Med 1995; 333: 269-275
22. Frustaci A, Chimenti C. Immunosuppressive therapy in myocarditis. Circ J 2014; 79: 4-7
23. Tajiri K, Yasutomi Y, Aonuma K. Recent advances in the management of autoimmune myocarditis: insights from animal studies. Current Pharm Des 2016; 22: 427-439
24. Afanasyeva M, Rose N. Viral infection and heart disease autoimmune mechanisms. In: Shoenfeld Y, Agmon-Levin N, Rose N, editors. Infection and Autoimmunity, 2nd edn. Amsterdam: Academic Press; 2004. pp. 299-318
25. Li HS, Ligons DL, Rose NR. Genetic complexity of autoimmune myocarditis. Autoimmun Rev 2008; 7: 168-173
26. Noel R. Learning from myocarditis: mimicry, chaos and black holes. F1000Prime Rep 2014; 6: 25
27. Rose NR. Critical cytokine pathways to cardiac inflammation. J Interferon Cytokine Res 2011; 31: 705-710
28. Kania G, Siegert S, Behnke S, et al. Innate signaling promotes formation of regulatory nitric oxide-producing dendritic cells limiting T-cell expansion in experimental autoimmune myocarditis. Circulation 2013; 127: 2285-2294
29. Barin JG, Baldeviano GC, Talor MV, et al. Fatal eosinophilic myocarditis develops in the absence of IFN-and IL-17A. J Immunol 2013; 191: 4038-4047
30. Ong S, Ligons DL, Barin JG, et al. Natural killer cells limit cardiac inflammation and fibrosis by halting eosinophil infiltration. Am J Pathol 2015; 185: 847-861
31. Baldeviano GC, Barin JG, Talor MV, et al. Interleukin-17A is dispensable for myocarditis but essential for the progression to dilated cardiomyopathy. Circ Res 2010; 106: 1646-1655
32. Wu L, Diny NL, Ong S, et al. Pathogenic IL-23 signaling is required to initiate GM-CSF-driven autoimmune myocarditis in mice. Eur J Immunol 2016; 46: 582-592